Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JSKN016 for advanced lung cancer
CTR20244774Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of JSKN016 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 arms), sponsored by Kanion Pharmaceutical. Primary endpoints: Objective response rate (ORR) - Part 1, Safety endpoints - Part 1 and 1 more. Started Jan 2025; status: active.
02
Drugs
JSKN016
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20244774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244774.